Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin plus /- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).

被引：0
|
作者：
Sahai, Vaibhav
Griffith, Kent A.
Zhen, David Bing
Deming, Dustin A.
Shroff, Rachna T.
Hsieh, David
Mahalingam, Devalingam
Crysler, Oxana V.
Alistar, Angela Tatiana
Bajor, David L.
Enzler, Thomas
Zalupski, Mark
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Univ Michigan, Ctr Canc Biostat, Sch Publ Hlth, Ann Arbor, MI USA
[3] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] Univ Arizona, Canc Ctr, Tucson, AZ USA
[6] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Atlantic Hlth Syst, Carol G Simon Canc Ctr, Morristown, NJ USA
[9] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4116
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Zhen, David Bing
    Crysler, Oxana V.
    Beg, Shaalan Shaalan
    Enzler, Thomas
    Griffith, Kent A.
    Zalupski, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Chang, Amy E.
    Crysler, Oxana V.
    Zhen, David Bing
    Beg, Muhammad Shaalan
    Pardee, Timothy S.
    Luther, Sanjeev
    Griffith, Kent A.
    Zalupski, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)
    Sahai, V.
    Chang, A.
    Crysler, O.
    Zhen, D.
    Luther, S.
    Zalupski, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S160 - S160
  • [4] Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
    Borad, Mitesh J.
    Bai, Li-Yuan
    Richards, Donald
    Mody, Kabir
    Hubbard, Joleen
    Rha, Sun Young
    Soong, John
    McCormick, Daniel
    Tse, Emmett
    O'Brien, Daniel
    Bayat, Ahmad
    Ahn, Daniel
    Davis, S. Lindsey
    Park, Joon Oh
    Oh, Do-Youn
    [J]. HEPATOLOGY, 2023, 77 (03) : 760 - 773
  • [5] Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
    Mohan, Arathi
    Grif, Kent A.
    Wuchu, Fulei
    Zhen, David B.
    Kumar-Sinha, Chandan
    Crysler, Oxana
    Hsiehchen, David
    Enzler, Thomas
    Dippman, Dominique
    Gunchick, Valerie
    Achreja, Abhinav
    Animasahun, Olamide
    Choppara, Srinadh
    Nenwani, Minal
    Chinnaiyan, Arul M.
    Nagrath, Deepak
    Zalupski, Mark M.
    Sahai, Vaibhav
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2394 - 2400
  • [6] ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced biliary tract cancer.
    Bridgewater, John A.
    Beare, Sandy
    Dymphna, Lee
    Lopes, Andre
    Duggan, Marian
    Wasan, Harpreet S.
    Valle, Juan W.
    McEntee, Delyth
    Ricamara, Marivic
    Sukumaran, Ajithkumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
    Bridgewater, John
    Lopes, Andre
    Beare, Sandra
    Duggan, Marian
    Lee, Dymphna
    Ricamara, Maravic
    McEntee, Delyth
    Sukumaran, Ajithkumar
    Wasan, Harpreet
    Valle, Juan W.
    [J]. BMC CANCER, 2016, 16
  • [8] A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
    John Bridgewater
    Andre Lopes
    Sandra Beare
    Marian Duggan
    Dymphna Lee
    Maravic Ricamara
    Delyth McEntee
    Ajithkumar Sukumaran
    Harpreet Wasan
    Juan W. Valle
    [J]. BMC Cancer, 16
  • [9] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [10] Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
    John Bridgewater
    Andre Lopes
    Sandra Beare
    Marian Duggan
    Dymphna Lee
    Maravic Ricamara
    Delyth McEntee
    Ajithkumar Sukumaran
    Harpreet Wasan
    Juan W. Valle
    [J]. BMC Cancer, 16
12345